ImageneBio Statistics
Total Valuation
ImageneBio has a market cap or net worth of $67.09 million. The enterprise value is -$65.28 million.
Important Dates
The last earnings date was Tuesday, March 10, 2026, before market open.
| Earnings Date | Mar 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImageneBio has 11.18 million shares outstanding. The number of shares has increased by 148.26% in one year.
| Current Share Class | 10.65M |
| Shares Outstanding | 11.18M |
| Shares Change (YoY) | +148.26% |
| Shares Change (QoQ) | -5.51% |
| Owned by Insiders (%) | 1.56% |
| Owned by Institutions (%) | 20.80% |
| Float | 6.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 83.86 |
| Forward PS | n/a |
| PB Ratio | 0.48 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.49, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.49 |
| Quick Ratio | 12.05 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -68.91% and return on invested capital (ROIC) is -42.46%.
| Return on Equity (ROE) | -68.91% |
| Return on Assets (ROA) | -35.86% |
| Return on Invested Capital (ROIC) | -42.46% |
| Return on Capital Employed (ROCE) | -34.18% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -350,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 6.75 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 38.44 |
| Average Volume (20 Days) | 32,401 |
Short Selling Information
The latest short interest is 378,568, so 3.39% of the outstanding shares have been sold short.
| Short Interest | 378,568 |
| Short Previous Month | 369,759 |
| Short % of Shares Out | 3.39% |
| Short % of Float | 6.04% |
| Short Ratio (days to cover) | 1.31 |
Income Statement
In the last 12 months, ImageneBio had revenue of $800,000 and -$52.40 million in losses. Loss per share was -$10.76.
| Revenue | 800,000 |
| Gross Profit | 800,000 |
| Operating Income | -48.45M |
| Pretax Income | -45.70M |
| Net Income | -52.40M |
| EBITDA | -48.05M |
| EBIT | -48.45M |
| Loss Per Share | -$10.76 |
Full Income Statement Balance Sheet
The company has $135.35 million in cash and $2.98 million in debt, with a net cash position of $132.37 million or $11.84 per share.
| Cash & Cash Equivalents | 135.35M |
| Total Debt | 2.98M |
| Net Cash | 132.37M |
| Net Cash Per Share | $11.84 |
| Equity (Book Value) | 133.14M |
| Book Value Per Share | 12.50 |
| Working Capital | 129.05M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -47.84M |
| Capital Expenditures | n/a |
| Free Cash Flow | -47.84M |
| FCF Per Share | -$4.28 |
Full Cash Flow Statement Margins
| Gross Margin | 100.00% |
| Operating Margin | -6,056.38% |
| Pretax Margin | -5,712.38% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ImageneBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -148.26% |
| Shareholder Yield | -148.26% |
| Earnings Yield | -78.10% |
| FCF Yield | -71.31% |
Analyst Forecast
The average price target for ImageneBio is $16.00, which is 166.67% higher than the current price. The consensus rating is "Hold".
| Price Target | $16.00 |
| Price Target Difference | 166.67% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 91.69% |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |